Introduction
Acute promyelocytic leukemia (APL), a clonal expansion of hematopoietic precursors blocked at the promyelocytic stage, is associated with specific chromosomal translocations that produce different fusion proteins, including PML-RARa, 1 which retains most functional domains of the RARa protein and that can still bind to retinoic acid (RA) and to its response elements on DNA, but competes with normal RARa with a dominantnegative effect on PML and RARa signaling. 2 In addition, in myeloid cells PML-RARa can suppress the basal transcription by recruitment of histone deacetylases (HDAC). 3 In the late 1980s, it was found that pharmacological doses of all-trans retinoic acid (ATRA) were able to relieve this repression by inducing PMLRARa fusion protein degradation and promoting cell cycle arrest and differentiation of the leukemic blasts. 1 On the basis of such evidence, ATRA is clinically used for patients with APL, resulting in complete remission in more than 90% of cases: 4, 5 the blockage is abolished and promyelocytes differentiate into granulocytes and follow the natural pathway to cell aging. However, ATRA does not completely eradicate the malignant clones and patients eventually relapse. When this happens, ATRA alone fails to induce a second remission in the majority of the patients. 5 The observation that PML-RARa can suppress gene transcription by recruitment of HDAC suggested the possibility that the inhibition of HDAC activity may restore APL sensitivity to ATRA and that retinoids used in combination with HDAC inhibitors could obtain clinical remission also in ATRA-resistant APL patients. In vitro experiments have in fact demonstrated that RA, in combination with an HDAC inhibitor (trichostatin A or sodium butyrate), can induce growth arrest and differentiation, 3 and a preliminary clinical study has shown that combined treatment with RA and phenylbutyrate provided long-lasting complete remission in one patient with ATRA-refractory APL. 6 The putative synergistic interaction between retinoids and HDAC inhibitors induced us to develop a novel retinoic/butyric hyaluronan ester (HBR) in which hyaluronan, a natural polymer able to bind to a specific membrane receptor (CD44), was contemporaneously esterified with butyric acid (the smallest HDAC inhibitor) and RA. 7 Hyaluronan is a very suitable carrier mainly because of its high chemical versatility and good biocompatibility, being one of the main constituents of the extracellular matrix; it is selectively taken up by CD44 that is overexpressed in most human cancers including leukemia cells, 8 and it provides an efficient route to internalize the compound. In the present in vitro/in vivo study, we explored the pharmacological potential of HBR on a RA-sensitive leukemiaderived human myeloid cell line, NB4, on its RA-resistant subclone NB4.007/6 and on the murine P388 lymphocytic leukemia, a naturally RA-resistant cell line.
Materials and methods

Chemistry
The butyric and retinoic mixed ester of hyaluronic acid, HBR, was synthesized as described elsewhere. 7 Briefly, we prepared a double salt of tetrabutylammonium with two functional groups of hyaluronan, specifically its carboxyl and 6-hydroxyl, in order to achieve good solubility in polar aprotic organic solvents and to increase the nucleophilicity of the oxygen atom at C-6. Retinoylation with retinoyl chloride, which is the rate-limiting step, was carried out before butyrylation by means of butyric anhydride and 4-(dimethylamino)pyridine as a hypernucleophilic acylation catalyst. 9 The degrees of substitution with butyric and retinoic acid, defined as the fractions of esterified 6-hydroxyl groups, were determined to be 1.0 and 0.028, respectively.
Cell culture, cell growth experiments and nitroblue tetrazolium assay
The in vitro activity of HBR with respect to RA, alone or in association with the sodium salt of butyric acid (NaB), was evaluated in a human RA-sensitive leukemia cell line (NB4, derived from a patient with APL and characterized by a specific 15;17 chromosomal translocation) and in its RA-resistant subclone NB4.007/6 obtained and maintained under continuous selective pressure of 10 À6 M RA. 10 Cells were kindly provided by Dr Gambacorti-Passerini (Istituto Nazionale Tumori) and were maintained in complete RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% (vol/vol) fetal bovine serum (FBS) in T-75 cm 2 plastic flasks in a 5% CO 2 humidified atmosphere at 371C and passaged weekly by serial dilution. Mycoplasma-free cells were seeded in 96-wells per plate (1000 cells per well) in RPMI-1640 medium supplemented with 10% FBS and in the presence of increasing concentrations of HBR (0.001-2 mg/ml), RA (10
À9
-10 À5 M), NaB (0.001-4 mM), singly or in association, and hyaluronic acid (0.001-2 mg/ml) for 6 days, a sufficient interval to observe a significant difference in the cell growth with respect to control. Each experiment was performed at least twice and samples were run in eight replicates. At the end of the experiments, the antiproliferative effect was evaluated using Alamar Blue (BioSource Inc., Camarillo, CA, USA), a suitable colorimetric method for floating cells. Wells containing all admixtures except cells were used as blanks and IC 50 was defined as the concentration of drug that inhibited cell growth by 50% compared to control. Differences between IC 50 values were statistically assessed with Student's ttest. Similar studies were conducted also on P388 lymphocytic leukemia cells and to look at HBR effects on normal peripheral blood cells, growth experiments were performed also on normal lymphocytes isolated from a buffy coat as detailed in Supplementary Information. The induction of a terminal differentiation by 0.1 mg/ml HBR, 0.22 mM NaB or 5.8 Â 10 À6 M RA (singly or in association) in NB4 or NB4.007/6 cells was assessed by the nitroblue tetrazolium (NBT) assay as detailed in Supplementary Information.
Flow cytometry for cell cycle perturbations, CD44 and differentiation-associated antigen expression Cell cycle perturbations induced by a 72-h treatment (an interval sufficient to observe cell cycle perturbations but not a significant antiproliferative effect) with 0.1 mg/ml HBR (corresponding to the IC 90 value observed after 6 days of treatment in growth inhibitory experiments), 5.8 Â 10 À6 M RA or 0.22 mM NaB (the concentrations of NaB and RA present in 0.1 mg/ml HBR) were evaluated by quantifying the DNA content of cells with the fluorescent intercalating agent propidium iodide, as elsewhere described. 11 The effect induced on the expression of various granulocyte differentiation-associated antigens by a 72-h treatment with increasing concentrations of HBR (0.001-1 mg/ml), RA (5.8 Â 10 À8 -10 À5 M), NaB (0.022-2.2 mM), alone or in association, was evaluated using specific anti-human murine monoclonal antibodies (MO782 for CD11a, MO741 for CD11b, MO732 for CD11c and MO733 for CD15, all from DAKO, Glastrup, Denmark, details in Supplementary Information), whereas the presence of CD44 receptor, a fundamental requirement for the internalization of hyaluronan derivatives, was evaluated, as elsewhere described, 12 in NB4, NB4.007/6, P388 leukemic cells and in normal lymphocytes. In this latter, the modulatory effect of HBR on CD44 expression was also evaluated. All cell lines expressed CD44 receptor in a very high percentage (99% for NB4 and NB4.007/6, 97% for lymphocytes and 70% for P388), which was not affected by HBR treatment either in leukemic cells (data not shown) or in normal lymphocytes with or without phytohemagglutinin (PHA) stimulation (Supplementary Table 1 ).
Extraction of cellular histones and Western blot analysis for acetylated histone H4 expression
To evaluate the early effect on histone H4 acetylation, cells were treated with 0.22 mM NaB, 5.8 Â 10 À6 M RA, singly or in association, and 0.1 HBR for 6 h. About 4 Â 10 6 cells were washed with ice-cold phosphate-buffered saline and suspended in 1 ml of ice-cold lysis buffer (10 mM TRIS-HCl, 50 mM sodium bisulfite, 10 mM MgCl 2 , 1% Triton X-100, 8.6% sucrose). After homogenization, the nuclei were collected by centrifugation at 1000 Â g for 10 min, washed three times with lysis buffer without Triton X-100 and once with 10 mM TRIS-HCl, 13 mM EDTA, pH 7.4. The pellet was suspended in 0.15 ml of H 2 SO 4 0.25 M and 0.5% b-mercaptoethanol. After incubation at 41C for 2.5 h, the suspension was centrifuged for 5 min at 15 000 Â g, and the supernatant was mixed with 1 ml of acetone. After overnight incubation at À201C, the coagulated material was collected by microcentrifugation and air-dried. This acid soluble histone fraction was dissolved in 50 ml of H 2 O and 0.5% b-mercaptoethanol. Protein concentration was quantified using a protein assay kit (Bio-Rad). Isolated histones (10 mg) were separated on 15% SDS-PAGE minigels and transferred on to nitrocellulose. Acetylated histone H4 was detected using a rabbit polyclonal antibody (clone 6598, Upstate Biotechnology, New York, NY, USA). As a control for the amount of protein loading, gels were stained with Coomassie Blue according to He et al. 13 The results (mean of three independent experiments) were expressed as densitometric units (DU).
Western blot analysis of apoptosis-related proteins and PML-RARa protein expression
To evaluate caspase 3, caspase 7 and PML-RARa protein levels, cells were treated with 5.8 Â 10 -6 M RA, 0.22 mM NaB, singly or in association, or 0.1 HBR for 48 h (an interval sufficient to observe protein modulation but not a significant antiproliferative effect). Protein levels were evaluated by Western blotting (see Supplementary Information) using mouse monoclonal antibodies for caspase 3, caspase 7 (clone AB7850 and AB3246, respectively, which recognized also the activated form, Abcam, Cambridge, UK) and RARa protein (clone 5346, Chemicon, Temecula, CA, USA) and the results, which represent the mean of three independent experiments, were expressed as foldincrease with respect to control.
RNA preparation and reverse transcriptase-polymerase chain reaction for PML-RARa
To evaluate the effect of the compounds on PML-RARa mRNA expression level, cells were treated with 5.8 Â 10 À6 M RA, 0.22 mM NaB, alone or in combination, or 0.1 HBR for 48 h. Total RNA was then extracted and the amplification of PMLRARa was obtained using the following primer sequences: sense 
C/EBPa and C/EBPb binding activity
The effect of a 48-h treatment with 0.1 mg/ml HBR, 5.8 Â 10 À6 M RA, 0.22 mM NaB, singly or in association, on C/EBPa and C/EBPb transcription factor binding activity was evaluated using a recently commercialized C/EBPa and C/EBPb transcription factor Elisa-based assay kit (TransAM; Active Motif Europe, Rixensart, Belgium), which consists of a 96-well plate coated with an oligonucleotide containing the C/EBP consensus binding site (5 0 -GCAAT-3 0 ), recognized by C/EBPa or C/EBPb present in nuclear extracts. The addition of a specific primary antibody against C/EBPa or C/EBPb and of a secondary antibody conjugated to horseradish peroxidase provided a sensitive colorimetric readout, measurable at 450 nm with a reference wavelength of 655 nm. Each sample was run in triplicate and the results (expressed as optical density, OD 450 ) were further validated on the same samples by a radioactive electrophoretic mobility shift assay (EMSA) performed as detailed in Supplementary Information.
Chromosomal immunoprecipitation assay
Chromosomal immunoprecipitation (ChIP) analysis was performed on DNA obtained from 5 Â 10 6 cells treated for 6 h with 5.8 Â 10 À6 M RA, 0.22 mM NaB, singly or in association, and 0.1 mg/ml HBR, using the ChIP kit (Upstate Biotechnology, New York, NY, USA) according to the manufacturer's instructions with minor modifications. Protein/DNA complexes were immunoprecipitated by using an antiacetylated histone H4 antibody (Upstate), and immunoprecipitated DNA was isolated and subsequently detected by sequence-specific PCR for RARb promoter sequences and run in agarose gel. The results (mean of three independent experiments) were expressed as NDU.
In vivo studies
To investigate the in vivo effect of HBR we used a SCID/NB4 model 14 and the P388 lymphocytic leukemia 15 in DBA mice. Forty-five female severe combined immunodeficient (SCID) mice (Harlan, Italy), intraperitoneally inoculated on day 0 with 6 Â 10 6 NB4 cells, were randomized in five experimental groups (9 animals/group) and treated daily with vehicle (controls), RA at the dose of 15 mg/kg (the maximal tolerated dose), HBR at a dose of 1.6 mg/mouse (corresponding to 1.5 mg/kg of RA and 25 mg/kg of NaB), NaB at the dose of 25 mg/kg or with the combination of RA (1.5 mg/kg) plus NaB (25 mg/kg). Retinoic acid was dissolved in the dark in Cremophor EL (Sigma) and kept magnetically stirred whereas HBR and NaB were dissolved in physiological solution. Drugs were intraperitoneally administered 3 days after tumor inoculation and each treatment continued for 13 days (5 daily injections/week). 16 In female DBA/2 mice (Harlan, Italy), inoculated with 10 6 P338 lymphocytic leukemic cells, the treatments started one day after tumor implantation and continued for 6 consecutive days. 
Results
Hyaluronan ester induced growth arrest and differentiation in retinoic acid-sensitive NB4 cells
After 6 days of treatment, HBR induced a dose-dependent inhibition (up to 90%) of NB4 cell growth already at the concentration of 0.1 mg/ml, corresponding to 5.8 Â 10 À6 M RA and 0.22 mM butyric acid concentration (Supplementary Figure  1) and when compared to the activity of NaB alone, it induced an about five-fold decrease in the IC 50 value (0.02 vs 0.1 mM, Po0.05). Conversely, HBR did not improve the antiproliferative effect induced by RA, alone or in combination with NaB, which almost completely inhibited the growth of this RA-responsive 
NB4
NB4.007/6 Figure 1 Hyaluronan ester (HBR) modulates the expression of differentiation-specific antigens in NB4 but not in NB4.007/6 cells. The effect of scalar concentrations of sodium salt of butyric acid (NaB) (0.0022-2.2 mM, &), retinoic acid (RA) (10 À7 -10 À4 M, J), the association NaB plus RA (}) or HBR (containing the corresponding concentration of NaB and RA, n), on the expression of CD11a, CD11b, CD11c and CD15 was evaluated on RA-sensitive NB4 and RA-resistant NB4.007/6 cell lines. An induction of all the granulocyte differentiation antigens was observed only in NB4 cells, whereas in the RA-resistant cell line an increase of CD11c and CD15 expression was observed only at the highest concentration. Since CV was o5%, s.d. are not reported.
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À7 M. Similarly to RA, HBR induced cell differentiation as demonstrated by the NBT assay (data not shown) and confirmed by the increased expression of all the granulocyte differentiation antigens belonging to the CD11 family and of the CD15 antigen ( Figure 1) . Indeed, compared to controls, HBR increased the expression of CD11a, CD11b and CD15 already at the concentration of 0.001 mg/ml and induced the re-expression of CD11c (from 3 to 98%).
Hyaluronan ester inhibited the growth of retinoic acid-resistant NB4/007.6 cells by apoptosis
In RA-resistant NB4.007/6 cells, HBR completely inhibited cell growth at the concentration of 1 mg/ml (Supplementary Figure  1) , corresponding to 5.8 Â 10 À5 M RA and 2.2 mM NaB. However, unlike the RA-sensitive cell line, this effect was not accomplished by the induction of granulocyte differentiation even though an increase of CD11c and CD15 expression was observed at the highest concentration (Figure 1 ). The lack of differentiation was also confirmed by the NBT assay (data not shown). Similarly to NaB, HBR induced a remarkable pre-G 0/1 apoptotic peak (Figure 2a) paralleled by a five-to six-foldincrease, vs untreated controls, of the activated caspase 3 (17 kDa fragment) and 7 (20 kDa fragment) protein levels ( Figure 2b ).
Hyaluronan ester did not affect lymphocytes proliferation
To study the effect on normal blood cells, lymphocytes were isolated from a buffy coat and treated with scalar concentrations of hyaluronan ester in the presence or absence of PHA. HBR did not affect the growth of lymphocytes, even if activated by PHA and despite their high expression of CD44 receptor (98%), suggesting a specific HBR activity on tumor cells (Supplementary Figure 2) .
Hyaluronan ester induced histone H4 hyperacetylation and specific acetylation of RARb promoter
In view of its butyrate moiety, the HDAC-inhibiting activity of HBR was compared to that exerted by NaB. The cells showed a different basal histone H4 acetylation: NB4.007/6 had an about five-fold higher basal level than NB4 cells (Figure 3a) . A 6-h treatment with HBR increased the total histone H4 acetylation level of about eight-and two-fold with respect to untreated control, respectively in retinoic acid-sensitive and RA-resistant cells; albeit to a lesser extent than NaB, probably because of the higher hyperacetylating efficiency of the free active principle. Consistent with previous reports showing RARb as a marker for RA-induced granulocytic differentiation, 17 we examined the specific acetylation of RA response element in the RARb promoter, by the ChIP assay, finding that, like RA, HBR induced hyperacetylation of the RARb promoter (Figure 3b ) only in RAsensitive NB4 cells, in agreement with the differentiation effect observed in this cell line. Conversely, none of the treatments induced acetylation of the RARb promoter in the RA-resistant NB4.007/6 cell line, supporting the hypothesis of the shift towards apoptosis in these latter cells.
Hyaluronan ester effect on C/EBPa and C/EBPb binding activity
Among the genes assumed to be pivotal for the myeloid differentiation, there are members of the family of C/EBP transcription factors, the expression of which is induced in APL cells by RA treatment in parallel with the granulocyte differentiation. 18 We therefore investigated the effect of 0.1 mg/ ml HBR on the binding activity of C/EBPa and C/EBPb transcription factors. The two cell lines responded in a very different manner (Figure 4a ): in the RA-sensitive NB4 cells HBR slightly decreased the C/EBPa binding activity (À40%, P ¼ 0.05) and markedly increased the C/EBPb binding activity ( þ 700%, P ¼ 0.001), whereas in the RA-resistant NB4.007/6 cells HBR increased the C/EBPa ( þ 60%, Po0.05) and did not affect the À6 M RA, the control coincides with RA alone; NaB corresponds to RA plus NaB.
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Hyaluronan ester reduced PML-RARa protein but not mRNA expression NB4 and NB4.007/6 cells expressed comparable levels of PMLRARa mRNA (data not shown) but not of its corresponding protein, which was higher in the RA-sensitive cell line (Figure 4b) . After a 48-h treatment with 0.1 mg/ml HBR, both cell lines showed a statistically significant reduction of the PML-RARa protein concentration more evident in the RA-sensitive one (À74%, Po0.01 in NB4 cells and À56%, Po0.05 in NB4.007/6 cells), not paralleled by a concomitant modulation of the corresponding mRNA expression (data not shown). Particularly in NB4 cells, the HBR-induced effect was more marked than that of the association of RA with NaB, suggesting that the covalent binding of the two active principles to a hyaluronan carrier may potentiate their biological activity. (a) Representative acetylating effect of a 6-h treatment with sodium salt of butyric acid (NaB), retinoic acid (RA), RA plus NaB and HBR on histone H4. Since NB4.007/6 cells were always cultured in the presence of 10 À6 M RA the control coincides with RA alone; NaB corresponds to RA plus NaB. The graphs show the mean densitometric units obtained from three independent experiments; bars: standard deviation. (b) Chromosomal immunoprecipitation assay of NB4 and NB4.007/6 cells treated for 6 h with NaB, RA, RA plus NaB or HBR. Since NB4.007/6 cells were always cultured in the presence of 10 À6 M RA the control coincides with RA alone; NaB corresponds to RA plus NaB. Immunoprecipitated DNA was detected by sequence-specific PCR for RARb promoter sequences and run in agarose gel. Input: amplification of 1% of the total material used for immunoprecipitation. NDU, normalized densitometric units; the graphs show the mean NDU obtained from three independent experiments; bars: standard deviation.
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Hyaluronan ester efficacy in vivo
To determine the in vivo antileukemic activity of HBR, SCID mice were intraperitoneally inoculated with NB4 cells. Figure 5a shows that intraperitoneally administration of HBR at the dose of 1.6 mg/mouse, corresponding to 1.5 mg/kg RA and 25 mg/kg NaB, was accompanied by a significant increase in the overall survival of leukemia-bearing mice (Po0.0001). The antileukemic effect of HBR was comparable to that obtained with 15 mg/kg RA, which represents the maximum tolerated dose for this experimental schedule. 16 Conversely, NaB alone or in association with RA, at the doses equivalent to HBR, did not improve animal survival and a similar result was obtained using RA alone, at the dose of 1.5 mg/kg (data not shown). Since in vitro P388 cells resulted RA-resistant (with a cytotoxic effect at a concentration X10 À4 M) but highly responsive to HBR, which induced 90% inhibition at 0.1 mg/ml (data not shown), we investigated HBR efficacy in DBA/2 mice intraperitoneally inoculated with P388 cells. Also in this case HBR, at the dose of 1.6 mg/mouse, induced a significant increase in overall survival (Po0.001), whereas NaB 
Discussion and conclusion
To overcome RA resistance in APL patients by the concurrent administration of a retinoid and of an HDAC inhibitor, we developed HBR, a novel mixed retinoic/butyric ester. The results show that HBR blocks cell growth in both retinoic acid-sensitive and RA-resistant cell lines and induces terminal granulocytic differentiation in RA-sensitive NB4 cells (as confirmed by the increased expression of the CD11 family members and NBT assay) and apoptosis in the RA-resistant NB4.007/6 cells (as demonstrated by the increased levels of the activated form of caspases 3 and 7), probably due to the butyric moiety of the compound. 19 This dual cellular effect (differentiation vs apoptosis) is also supported by the finding that HBR induces specific acetylation in the RA response element of the RARb promoter (reported as a marker for RA-induced granulocytic differentiation) enhancing RA-mediated cell differentiation in RA-sensitive cells. This finding is corroborated by the observation that, in NB4 cells unlike in RA-resistant cells, HBR substantially increases the binding capability of C/EBPb, a transcription factor involved in myeloid differentiation pathways. In addition, a 48-h treatment of RA-sensitive cells with 0.1 mg/ml HBR, corresponding to 5.8 Â 10
À6 M RA and 0.22 mM NaB, significantly decreased the expression of PML-RARa protein, suggesting that the covalent binding of the two active principles on a common carrier may restore RA biological efficacy. The antiproliferative effect observed in vitro on NB4 cells is confirmed by in vivo significant prolongation of the life time expectancy in treated SCID mice. Kaplan-Meier survival curves indicate that HBR increased the host life span similarly to maximum tolerated doses of RA alone. Thus, the esterification of the two active principles on the same HA backbone leads to a pharmacological effect clearly superior to that of the individual agents, NaB and RA, probably allowing an increase of the short NaB half life time in vivo and an enhancement of the RA activity. 16 Also, the inefficacy of the two hyaluronan monoesters is probably due to the competition of the two monoesters for the same receptor, as previously observed by Ventura et al. 7 Moreover, in vivo results demonstrate the good biocompatibility of HBR with respect to RA. In fact, the effect of HBR on the overall survival of NB4-inoculated animals is similar to that observed administering a dose 10-fold higher of RA alone. This effect is more evident in mice inoculated with the RA-naturally resistant P388 leukemia in which only HBR was active. Since the elimination of proliferating leukemia cells is the main goal in the cure of APL patients, the present findings suggest that, owing to the simultaneous presence of RA and of an HDAC inhibitor, HBR could be useful in controlling either the proliferation of RAresistant cells or the differentiation of RA-sensitive cells. Clearly, other retinoid/HDAC inhibitor associations are currently under investigation 6, 20 and so are novel compounds, 17 both with promising results. However, such associations and novel drugs do not selectively target tumor cells. Conversely, HBR, due to its strong affinity for the CD44 membrane receptor 12 could be a promising antineoplastic agent for APL patients regardless of their possible resistance to RA, especially considering that antileukemic effects have been obtained using a suboptimal dose, thus suggesting the possibility to administer HBR at higher doses or to prolong the treatment to further improve its therapeutic effect. In vivo activity of hyaluronan ester (HBR) in the SCID/NB4 model and P388 lymphocytes leukaemia. (a) Severe combined immunodeficient (SCID) mice (9 animals/experimental group) were intraperitoneally inoculated with 6 Â 10 6 NB4 cells on day 0. On day 3, animals were randomized in five groups receiving a daily dose of vehicle (control), sodium salt of butyric acid (NaB) (25 mg/kg), retinoic acid (RA) (15 mg/kg, corresponding to the maximally tolerated dose), the association RA plus NaB (1.5 and 25 mg/kg, respectively) and HBR (1.6 mg/mouse, corresponding to 1.5 mg/kg of RA and 25 mg/kg of NaB). Treatment was continued for 13 days. (b) Female DBA/2 mice (Harlan, Italy), inoculated with 10 6 P338 lymphocytic leukemic cells were given the same treatments for 6 consecutive days starting one day after cells inoculation. Kaplan-Meier analysis was used to compare the overall survival between the groups. In SCID model, (a) HBR and RA (15 mg/kg) were significantly different from controls and from other treated groups (Po0.0001, by log-rank test), whereas in DBA model (b) HBR was significantly different from all the other treated groups (Po0.001 by log-rank test).
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